My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 441

    1.

    Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

    Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC.

    Ann Intern Med. 2008 Feb 5;148(3):178-85.PMID: 18252681 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    When to start antiretroviral therapy in resource-limited settings.

    Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

    Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.PMID: 19620143 [PubMed - indexed for MEDLINE]Related articles

    3.

    Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.

    Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ.

    Arch Intern Med. 2002 Nov 25;162(21):2478-86.PMID: 12437408 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

    Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA.

    Ann Intern Med. 2001 Mar 20;134(6):440-50.PMID: 11255519 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

    Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators.

    Antivir Ther. 2005;10(1):41-52.PMID: 15751762 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]

    Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

    Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish. PMID: 17261244 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    The cost effectiveness of combination antiretroviral therapy for HIV disease.

    Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ.

    N Engl J Med. 2001 Mar 15;344(11):824-31.PMID: 11248160 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.

    Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA.

    Am J Public Health. 2001 Sep;91(9):1456-63.PMID: 11527782 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

    Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

    Ann Intern Med. 2003 Apr 15;138(8):620-6.PMID: 12693883 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

    Antiretroviral Therapy Cohort Collaboration.

    Lancet. 2008 Jul 26;372(9635):293-9.PMID: 18657708 [PubMed - indexed for MEDLINE]Related articles

    11.

    Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

    Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD.

    Lancet. 2008 Apr 26;371(9622):1443-51.PMID: 18440426 [PubMed - indexed for MEDLINE]Related articles

    12.

    Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

    Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR.

    AIDS. 2007 May 11;21(8):965-71.PMID: 17457090 [PubMed - indexed for MEDLINE]Related articles

    13.

    When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

    Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

    Antivir Ther. 2006;11(1):63-72.PMID: 16518961 [PubMed - indexed for MEDLINE]Related articles

    14.

    Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

    Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P.

    AIDS. 2008 Jul 11;22(11):1333-43.PMID: 18580613 [PubMed - indexed for MEDLINE]Related articles

    15.

    Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

    Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

    Clin Infect Dis. 2008 Mar 15;46(6):933-40.PMID: 18271750 [PubMed - indexed for MEDLINE]Related articles

    16.

    Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.

    Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group.

    J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5.PMID: 17971709 [PubMed - indexed for MEDLINE]Related articles

    17.

    Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

    Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

    N Engl J Med. 2005 Feb 10;352(6):570-85.PMID: 15703422 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

    AIDS. 2008 Aug 20;22(13):1583-8.PMID: 18670217 [PubMed - indexed for MEDLINE]Related articles

    19.

    HIV antiretroviral treatment: early versus later.

    Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J.

    J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):562-9.PMID: 16044008 [PubMed - indexed for MEDLINE]Related articles

    20.

    HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    Tamburrini E, Ravizza M, Floridia M, Tibaldi C, Alberico S, Anzidei G, Maccabruni A, Meloni A, Antoni AD, Mori F, Dalzero S, Conservan V, Pinnetti C, Ferrazzi E; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    Antivir Ther. 2008;13(4):519-27.PMID: 18672530 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is temporarily unavailable.

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    » See more...